- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05815511
Clinical Trial to Evaluate the Effect of a Probiotic Mixture on the Rosacea Evolution
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of a Probiotic Mixture on the Evolution and Treatment of Rosacea
The clinical trial has a randomized, double-blind, placebo-controlled design, in which the aim is to evaluate the effect of a probiotic mix, with a 12-week treatment, on the evolution of rosacea.
This 12 weeks of treatment are structured into three visits: Visit 1 (initial; week 0), Visit 2 (intermediate; week 6) and Visit 3 (final; week 12).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The three visits that make up the study and the actions to be carried out in each of them are described below:
Visit 1 (initial; week 0)
Once the informed consent is signed, a doctor trained for the study performs the initial interview where it is verified that the patient meets all the inclusion criteria and none of the exclusion criteria and their medical history.The investigator will proceed to assign the patient the next study participant number and, according to a previously prepared randomization list, the treatment that they will receive during the study will be assigned.
The investigator will assess the severity and symptoms of rosacea according to the Investigator's Global Assessment (IGA) and Clinician Erythema Assessment (CEA) scales. The patient will also complete a questionnaire to assess the impact on quality of life due to the disease: Dermatology Life Quality Index (DLQI).
Visit 2 (intermediate; week 6)
In this intermediate visit, in addition to assessing the symptoms of the disease with the detailed scales, the investigator will record the adverse events reported by the patient, as well as the concomitant treatments used.
Also, the treatment compliance rate will be calculated by counting the capsules returned by the patient.
Visit 3 (final; week 12)
In the final visit, the same actions will be carried out as in the intermediate visit, evaluating the severity of the disease and the remaining capsules will be collected, to calculate treatment compliance, concomitant treatments and adverse events.
Visit 4 (post-treatment follow-up; week 24)
During this visit, the symptoms of the disease will be assessed with the two scales used in the study and the treatments that the patient has required during the 12 weeks after the end of the study treatment will be counted.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Laura Navarro Moratalla
- Phone Number: +34 865780170
- Email: laura.navarro@bioithas.com
Study Contact Backup
- Name: Juan Gabriel Agüera Santos
- Phone Number: +34 623022586
- Email: juan.aguera@gmail.com
Study Locations
-
-
-
Madrid, Spain, 28006
- Recruiting
- Eguren Dermatology and Aesthetics Clinic
-
Contact:
- Cristina Eguren Michelena, MD
- Phone Number: +34 630 74 38 00
-
Murcia, Spain, 30107
- Recruiting
- MiBioPath UCAM Research Group
-
Contact:
- Vicente Navarro López, PhD
- Phone Number: +34 695845742
-
Salamanca, Spain, 37007
- Not yet recruiting
- Salamanca University Hospital. Dermatology Service
-
Contact:
- Daniel Rodríguez Baeza, MD
- Email: daniel.rodriguez.baeza@gmail.com
-
-
Pontevedra
-
Vigo, Pontevedra, Spain, 36201
- Recruiting
- Gavín Dermatologists Clinic
-
Contact:
- Juan García Gavín, MD
- Phone Number: +34 986 11 77 27
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients of both sexes of an age equal to or greater than 18 years.
- Patients diagnosed with papulopustular rosacea with a minimum score of 2 points according to the Investigator's Global Assessment (IGA) index.
- Signature of informed consent by the patient
Exclusion Criteria:
- Pregnant, lactating, and/or women who do not agree to use an effective contraceptive method during the development of the study.
- Allergy and/or intolerance to any of the components of the product under study.
- Consumption of antibiotics in the previous two weeks.
- Consumption of probiotics in the previous two months.
- Isotretinoin use in the previous six months.
- Light procedures (IPL, laser, Kleresca) in the previous three months.
- Participation in other clinical studies in the previous two months.
- Other dermatological pathologies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Probiotic group
Probiotic mixture in oral capsule format with selected strains in concentrations equal to or greater than 1x10^10 cfu/dose.
|
Oral capsule consumption once a day for 12 weeks
|
Placebo Comparator: Placebo group
Maltodextrin in oral capsule format
|
Oral capsule consumption once a day for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline in Investigator's Global Assessment (IGA) index score at 6, 12 and 24 weeks
Time Frame: 24 weeks
|
IGA index measures the severity of rosacea Score range is from 0 to 6 according to the severity of the disease 0=clear; 1=minimum; 2=mild; 3=mild-moderate; 4=moderate; 5=moderate-severe; 6=severe |
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline in Clinician Erythema Assessment (CEA) scale at 6, 12 and 24 weeks
Time Frame: 24 weeks
|
CEA scale measures the severity of rosacea Score range is from 0 to 4 according to the severity of the disease 0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe |
24 weeks
|
Number of days using concomitant treatments during the 12 weeks of intervention
Time Frame: 12 weeks
|
The number of days and the dose of concomitant treatments applied during the study will be counted, especially taking into account the consumption of:
|
12 weeks
|
Treatments used during the 12 weeks after completion of study treatment.
Time Frame: 12 weeks
|
The number of days and the dose of treatments applied during the 12 weeks after completion the study will be counted
|
12 weeks
|
Changes from baseline in Dermatology Life Quality Index (DLQI) at 6 and 12 weeks
Time Frame: 12 weeks
|
DLQI measures the impact rosacea has on your quality of life The index has 10 questions. Each question answered with "Very much" is counted with 3 points, "A lot" with 2, "Little" with 1, and "Not at all" as 0. The score obtained can range between 0 and 30 points, this being the worst possible score. |
12 weeks
|
Study treatment compliance rate at 6 and 12 weeks.
Time Frame: 12 weeks
|
The treatment adherence is collected, checking the number of remaining capsules in each of the visits
|
12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events at 6 and 12 weeks
Time Frame: 12 weeks
|
Adverse events reported by patients during follow-up at week 6 and week 12 visits are recorded
|
12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ROS.PROB
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rosacea
-
Amorepacific CorporationCompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaKorea, Republic of
-
Actavis Inc.CompletedModerate to Severe Papulopustular RosaceaUnited States
-
University of California, DavisCompletedRosacea | Ocular Rosacea | Cutaneous RosaceaUnited States
-
bioRASI, LLCCompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaUnited States
-
Galderma R&DCompleted
-
Cutera Inc.CompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaUnited States
-
Eye Associates of Central TexasWithdrawn
-
Dermata TherapeuticsActive, not recruiting
-
AiViva BioPharma, Inc.Withdrawn
-
Sol-Gel Technologies, Ltd.TerminatedPapulopustular RosaceaUnited States
Clinical Trials on Probiotic mixture
-
Massachusetts General HospitalWinclove Bio Industries BVActive, not recruitingInflammatory Bowel Diseases | Crohn Disease | Ulcerative ColitisUnited States
-
Policlinico HospitalUnknown
-
University of HelsinkiUnknownFood Hypersensitivity | Asthma | Atopic Dermatitis | Allergic Conjunctivitis | Allergic Rhinitis, SeasonalFinland
-
Hepatopancreatobiliary Surgery Institute of Gansu...CompletedHeart Valve DiseasesChina
-
AB Biotics, SACompleted
-
Agentschap NLWithdrawn
-
Bioithas SLBionou Research, S.L.Completed
-
Hadassah Medical OrganizationUnknownDiarrhea | Clostridium DifficileIsrael
-
Haydom Lutheran HospitalUniversity of Bergen; Helse Stavanger HF; Muhimbili University of Health and... and other collaboratorsActive, not recruitingNeonatal SepsisTanzania
-
University Hospital RijekaInstitute AllergoSanRecruitingObesity | IBS - Irritable Bowel SyndromeCroatia